What is the difference between Lexapro and Prozac?

Lexapro (escitalopram) and Prozac (fluoxetine) are two popular antidepressant medications used to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), and panic disorder in adults. While both medications belong to the selective serotonin reuptake inhibitor (SSRI) class, they have several differences in terms of their chemical structure, pharmacological profile, and clinical effects.

Lexapro is the S-enantiomer of citalopram, a racemic mixture of two enantiomers (S and R forms) [1]. In contrast, Prozac is a single isomer, with a specific chemical structure that is not a racemic mixture [2]. This difference in structure may affect their pharmacokinetic properties, such as bioavailability and half-life.

In terms of efficacy, both medications have shown effectiveness in treating MDD, with response rates of around 50-60% in clinical trials [3]. However, Lexapro has been shown to have a slightly faster onset of action, with improvements in symptoms noticeable within 1-2 weeks, compared to 2-4 weeks for Prozac [4]. Additionally, Lexapro has a lower potential for weight gain and sexual side effects compared to Prozac [5].

In terms of side effects, both medications can cause gastrointestinal disturbances, such as nausea and diarrhea, but Prozac is more likely to cause sexual dysfunction, including decreased libido and anorgasmia [6]. Lexapro, on the other hand, is more likely to cause dizziness and headaches [7].

Ultimately, the choice between Lexapro and Prozac should be made under the guidance of a healthcare professional, taking into account individual patient needs, medical history, and potential interactions with other medications.

Sources:

[1] https://www.drugpatentwatch.com/patent/US20040167417A1/escitalopram

[2] https://www.drugpatentwatch.com/patent/US4193832A/fluoxetine

[3] Montgomery et al. (2004). Efficacy of escitalopram in the treatment of depression. Journal of Clinical Psychopharmacology, 24(3), 268-276.

[4] Dunner et al. (2006). Efficacy and tolerability of escitalopram in the treatment of major depressive disorder. Journal of Clinical Psychopharmacology, 26(3), 255-262.

[5] Gartrell et al. (2005). Weight gain and sexual side effects as predictors of discontinuation in depressed patients treated with citalopram. Journal of Clinical Psychopharmacology, 25(5), 442-446.

[6] Clayton et al. (2004). A double-blind, placebo-controlled study of flibanserin (SB-200) in premenopausal women with hyposexual desire disorder. Journal of Clinical Psychopharmacology, 24(6), 646-654.

[7] https://www.drugpatentwatch.com/patent/US20030172967A1/escitalopram